## Apoptosis in Acute Myocardial Infarction **Key Point:** ACE inhibitors like enalapril reduce post-MI apoptosis by blocking angiotensin II–mediated programmed cell death and preventing adverse left ventricular remodeling. ### Mechanism of Enalapril in MI 1. **Blocks angiotensin II production** — reduces pro-apoptotic signaling via AT1 receptor 2. **Inhibits myocardial fibrosis** — prevents excessive collagen deposition and chamber dilation 3. **Reduces ventricular remodeling** — limits expansion of infarct zone and preserves ejection fraction 4. **Reduces mortality** — landmark trials (SAVE, AIRE, TRACE) demonstrated 20–27% mortality reduction **High-Yield:** ACE inhibitors are the only class of agents proven to reduce *apoptosis-mediated* cardiomyocyte loss specifically; they are indicated in all post-MI patients with reduced ejection fraction or anterior infarction, regardless of blood pressure. ### Why ACE Inhibitors Target Apoptosis Angiotensin II activates pro-apoptotic pathways through: - Increased reactive oxygen species (ROS) production - Activation of caspase cascades - Upregulation of pro-apoptotic Bcl-2 family members (Bax, Bad) - Suppression of anti-apoptotic factors (Bcl-2, Bcl-xL) ACE inhibitors break this cycle by reducing angiotensin II availability. **Clinical Pearl:** While beta-blockers (metoprolol) reduce heart rate and contractility (limiting necrosis extent), and aspirin prevents thrombosis, neither directly inhibits the apoptotic cascade. Enalapril is uniquely cardioprotective against programmed cell death. **Mnemonic:** **SAVE** (Survival and Ventricular Enlargement trial) — landmark trial proving ACE-I benefit post-MI; the drug *saves* the ventricle from apoptotic remodeling.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.